Primary African HIV clade A and D isolates: Effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B

AIDS Research and Human Retroviruses

Volumn 19, Issue 2, 2003, Pages 125-131

  Kitabwalla, Moiz ^a,b   Ferrantelli, Flavia ^a,b   Wang, Tao ^a,b   Chalmers, Alistair ^a   Katinger, Hermann ^c   Stiegler, Gabriela ^c   Cavacini, Lisa A ^a,d   Chou, Ting Chao ^e   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBOGY IGG1B12; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AFRICA; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS;

EID: 0037297663     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203762688630     Document Type: Article

References (50)

1. UNAIDS: AIDS epidemic update, 2002: http://www.unaids. org/epidemic_update
2. Moore JP and Burton DR: HIV-1 neutralizing antibodies: How full is the bottle? Nat Med 1999;5:142-144.
3. Ferrantelli F and Ruprecht RM: Neutralizing antibodies against HIV-back in the major leagues? Curr Opin Immunol 2002;14:495-502.
4. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
5. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Abdool-Karim S, and Montefiori DC: Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 2002;76:2233-2244.
6. Moog C, Fleury HJ, Pellegrin I, Kirn A, and Aubertin AM: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:3734-3741.
7. Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen L, and Nielsen JO: Autologous HIV-1 neutralizing antibodies: Emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquit Immune Defic Syndr 1992;5:303-307.
8. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Nystrom G, and Fenyö EM: Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990;4:107-112.
9. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, and Montefiori DC: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997;176:924-932.
10. Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, and Sodroski J: Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 1991;65:6188-6193.
11. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, and Parren PW: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892-10905.
12. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, and Katinger H: A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001;17: 1757-1765.
13. Xu W, Smith-Franklin BA, Li PL, Wood C, He J, Du Q, Bhat GJ, Kankasa C, Katinger H, Cavacini LA, Posner MR, Burton DR, Chou TC, and Ruprecht RM: Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol 2001;4:55-61.
14. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, Burton DR, and Parren PW: Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 2001;75:12198-12208.
15. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, and Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100-1108.
16. Verrier F, Nadas A, Gorny MK, and Zolla-Pazner S: Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolated 89.6. J Virol 2001;75:9177-9186.
17. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, and Ruprecht RM: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-206.
18. Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, Moore JP, and Tomer KB: Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001;75:10906-10911.
19. Li A, Baba TW, Sodroski J, Zolla-Pazner S, Gorny MK, Robinson J, Posner MR, Katinger H, Barbas CF III, Burton DR, Chou TC, and Ruprecht RM: Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses 1997;13:647-656.
20. Cavacini LA, Emes CL, Power J, Buchbinder A, Zolla-Pazner S, and Posner MR: Human monoclonal antibodies to the V3 loop of HVI-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr 1993;6:353-358.
21. + by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol 1998;72:3235-3240.
22. Tilley SA, Honnen WJ, Racho ME, Chou TC, and Pinter A: Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses 1992;8:461-467.
23. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, Ferrantelli F, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Chou TC, Andersen J, and Ruprecht RM: Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001;75:7470-7480.
24. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF III, Burton DR, Ho DD, et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-1gG. J Virol 1995;69:6609-6617.
25. Gao F, Yue L, Craig S, Thornton CL, Robertson DL, McCutchan FE, Bradac JA, Sharp PM, and Hahn BH: Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: Generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994;10:1359-1368.
26. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, et al.: Generation of human monoclonal antibodies against HIV-1 proteins: Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-369.
27. Burton DR, Pyati J, Koduri R, Sharp SJ. Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
28. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
29. Chou TC and Hayball M: CompuSyn: Multiple Drug Dose-Effect Analyzer and Manual. Biosoft, Cambridge, 1996.
30. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF III, and Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-4848.
31. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, and Burton DR: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1 → 2 mannose residues on the outer face of gp120. J Virol 2002;76: 7306-7321.
32. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
33. Baba M, Miyake H, Okamoto M, Iizawa Y, and Okonogi K: Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res Hum Retroviruses 2000;16:935-941.
34. Crawford JM, Earl PL, Moss B, Reimann KA, Wyand MS, Manson KH, Bilska M, Zhou JT, Pauza CD, Parren PW, Burton DR, Sodroski JG, Letvin NL, and Montefiori DC: Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol 1999;73:10199-10207.
35. Shibata R, Maldarelli F, Siemon C, Matano T, Parta M, Miller G, Fredrickson T, and Martin MA: Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing. J Infect Dis 1997;176:362-373.
36. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, Lin W, Montefiori DC, Lee-Parritz DE, Lu Y, Collman RG, Sodroski J, and Letvin NL: An env gene derived from a primary human immunodeficiency virus type I isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996;70:3198-3206.
37. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, and Letvin NL: A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996;70:6922-6928.
38. Li JT, Halloran M, Lord CI, Watson A, Ranchalis J, Fung M, Letvin NL, and Sodroski JG: Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol 1995;69:7061-7067.
39. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, and Birx DL: Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73:4009-4018.
40. Hofmann-Lehmann R, Rasmussen RA, Vlasak J, Smith BA, Baba TW, Liska V, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Posner MR, Cavacini LA, Chou TC, and Ruprecht RM: Passive immunization against oral AIDS virus transmission: An approach to prevent mother-to-infant HIV-1 transmission? J Med Primatol 2001;30:190-196.
41. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, and Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210.
42. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, and Burton DR: Antibody protects macaques against vaginal challenge with a pathogenic R6 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75:8340-8347.
43. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Williams AL, Wang T, Vlasak J, Montefiori DC, Ibegbu CC, Barry A, Cavacini LA, Katinger H, Stiegler G, Chou TC, Anderson DC, McClure HM, and Ruprecht RM: Post-exposure prophylaxis with human monoclonal antibodies: Protection of neonatal macaques against pathogenic SHIV89.6P infection or acute disease. AIDS 2002;17:201-209.
44. Mofenson LM and McIntyre JA: Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000;355:2237-2244.
45. Peckham C and Newell ML: Preventing vertical transmission of HIV infection [letter; comment]. N Engl J Med 2000;343:1036-1037.
46. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, Alnwick DJ, Rogers M, and Shaffer N: Prevention of mother-to-child HIV transmission in resource-poor countries: Translating research into policy and practice. JAMA 2000;283:1175-1182.
47. Lange JMA, PETRA Study Team: Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (PETRA study): A randomized, double-blind, placebo-controlled trial. Lancet 2002;359:1178-1186.
48. Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Dural M, Wisnewski A, Hammer S, Koziel C, Trapnell C, and Posner MR: Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 1998;14:545-550.
49. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N, and Katinger HW: A phase 1 trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002;16:227-233.
50. Schaad UB, Gianella-Borradori A, Perret B, et al.: Intravenous immune globulin in symptomatic pediatric human immunodeficiency virus infection. Eur J Pediatr 1998;147:300-303.